CTOR_OUT_1 [2025-03-25 16:32:05 -0400] 2080 Bytes | 564 tokens | Cum: 564 tkns (7.05% of 8k)
==========================================================================

Booyah, my friends! It's already 4:32:03 PM on Tue Mar 25, 2025 -0400, and I've got my eyes locked on Citius Oncology (CTOR), pushing up to 0.8481 from 0.71. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

Here's the first list of news for Citius Oncology:

C1 - Feb-14-25 04:30PM - Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
C2 - Feb-06-25 08:55AM - Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
C3 - Jan-07-25 08:08AM - Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
C4 - Jan-07-25 08:08AM 07:57AM - Citius Oncology to explore strategic alternatives
C5 - Jan-06-25 07:50AM - Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
C6 - Dec-31-24 07:10AM - Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital
C7 - Dec-27-24 05:00PM - Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
C8 - Dec-27-24 05:00PM 05:00PM - Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Citius Oncology (CTOR)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CTOR_OUT_3 [2025-03-25 16:32:07 -0400] 1039 Bytes | 270 tokens | Cum: 836 tkns (10.45% of 8k)
==========================================================================

Showing C1 (chunk 1 of 11): C1:
**Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update**
Date: Feb-14-25 04:30PM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-first-quarter-2025-financial-results-and-provides-business-update-302377259.html

CRANFORD, N.J.,Feb. 14, 2025/PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter endedDecember 31, 2024.

Fiscal First Quarter 2025 Business Highlights and Subsequent Developments

"During the first fiscal quarter of 2025, Citius Oncology advanced key initiatives to bring LYMPHIR to market and focused on exploring strategic options to maximi

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CTOR_OUT_5 [2025-03-25 16:32:09 -0400] 1040 Bytes | 232 tokens | Cum: 1070 tkns (13.38% of 8k)
==========================================================================

Showing C1 (chunk 2 of 11): ze shareholder value.  With FDA approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma (CTCL), we are determined to deliver this much-needed therapy to patients. LYMPHIR remains the only targeted systemic therapy approved for CTCL since 2018 and the only treatment with a mechanism of action that targets the IL-2 receptor. More than 84% of CTCL patients in the Phase III trial experienced skin relief from this debilitating disease," statedLeonard Mazur, Chairman and CEO of Citius Oncology.

"To support the long-term growth potential of LYMPHIR, we engaged Jefferies as our exclusive financial advisor to evaluate strategic alternatives. Active discussions are currently underway; our goal remains to bring LYMPHIR to market expeditiously. We are making strong progress toward our planned commercial launch in the first half of 2025. The inventory for launch is ready and our market ac

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CTOR_OUT_7 [2025-03-25 16:32:10 -0400] 873 Bytes | 259 tokens | Cum: 1331 tkns (16.64% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-24T21:05:45Z - 12 Health Care Stocks Moving In Monday's After-Market Session - Aspira Womens Health (NASDAQ:AWH), C...
A2 - 2025-03-18T12:07:56Z - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - bioAffinity Technologies (NASDAQ:BIAF...
A3 - 2025-03-17T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - BioAtla (NASDAQ:BCAB), Capstone Hold...
A4 - 2025-02-22T08:36:11Z - Citius Oncology (NASDAQ:CTOR) Stock Price Down 2.5% - What's Next?...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CTOR_OUT_9 [2025-03-25 16:32:12 -0400] 1038 Bytes | 315 tokens | Cum: 1648 tkns (20.60% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Monday's After-Market Session - Aspira Womens Health (NASDAQ:AWH), Capstone Holding (NASDAQ:CAPS)**Date: 2025-03-24Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44466107/12-health-care-stocks-moving-in-mondays-after-market-sessionGainers Tenon Medical TNON shares rose 43.1% to $1.4 during Monday's after-market session. The company's market cap stands at $4.3 million. As per the news, the Q4 earnings report came out 2 days ago. Know Labs KNW shares rose 17.14% to $1.23. The market value of their outstanding shares is at $3.4 million. OneMedNet ONMD stock increased by 12.84% to $0.65. The market value of their outstanding shares is at $18.1 million. Polyrizon PLRZ shares moved upwards by 10.28% to $0.83. The market value of their outstanding shares is at $3.6 million. Intensi

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CTOR_OUT_11 [2025-03-25 16:32:13 -0400] 1038 Bytes | 316 tokens | Cum: 1966 tkns (24.57% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): ty Therapeutics INTS stock increased by 8.91% to $2.2. The company's market cap stands at $33.3 million. Citius Oncology CTOR stock rose 8.57% to $0.76. The company's market cap stands at $54.3 million. Losers Capstone Holding CAPS shares fell 13.4% to $2.4 during Monday's after-market session. The market value of their outstanding shares is at $3.3 million. Coeptis Therapeutics COEP shares fell 7.97% to $8.66. The company's market cap stands at $28.0 million. Radiopharm Theranostics RADX stock declined by 7.89% to $5.27. The market value of their outstanding shares is at $40.9 million. Aspira Womens Health AWH shares declined by 6.88% to $0.09. The market value of their outstanding shares is at $1.5 million. Gelteq GELS shares fell 6.55% to $1.0. The company's market cap stands at $9.4 million. Kindly MD KDLY stock declined by 5.86% to $2.09. The market value of their outstanding shares

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CTOR_OUT_13 [2025-03-25 16:32:27 -0400] 981 Bytes | 336 tokens | Cum: 2304 tkns (28.80% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): is at $12.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

AWHAspira Womens Health Inc$0.08800.11%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum0.72Growth32.75Quality-Value36.25Price TrendShortMediumLongOverviewCAPSCapstone Holding Corp$2.6453.5%COEPCoeptis Therapeutics Holdings Inc$8.66-8.83%CTORCitius Oncology Inc$0.760022.6%GELSGelteq Ltd$1.00-5.66%INTSIntensity Therapeutics Inc$2.2010.0%KDLYKindly MD Inc$2.1039.1%KNWKnow Labs Inc$1.264.13%ONMDOneMedNet Corp$0.649920.4%PLRZPolyrizon Ltd$0.777039.2%RADXRadiopharm Theranostics Ltd$5.27-7.56%TNONTenon Medical Inc$1.4141.0%Market News and Data brought to you by Benzinga APIs

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CTOR_OUT_15 [2025-03-25 16:32:28 -0400] 267 Bytes | 67 tokens | Cum: 2615 tkns (32.69% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CTOR_OUT_17 [2025-03-25 16:32:31 -0400] 193 Bytes | 60 tokens | Cum: 2677 tkns (33.46% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
Document B1 not found. Only 0 articles available.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CTOR_OUT_19 [2025-03-25 16:32:33 -0400] 1036 Bytes | 331 tokens | Cum: 3037 tkns (37.96% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-14 10-Q PART I - FIN INFO

Item 1. Fin Stmnts.

CITIUS ONCOLOGY, INC.

COND CONS BAL SHEETS

(Unaudited)

December 31, 2024 September 30, 2024 Curr Assets: Cash and cash equiv $ 112 $ 112 Inventory 14,381,369 8,268,766 Prepaid expen...

S2 - 2025-02-14 10-Q PART I - FIN INFO

Item 1. Fin Stmnts.

CITIUS ONCOLOGY, INC.

COND CONS BAL SHEETS

(Unaudited)

December 31, 2024 September 30, 2024 Curr Assets: Cash and cash equiv $ 112 $ 112 Inventory 14,381,369 8,268,766 Prepaid expen...

S3 - 2024-12-27 8-K Item 2.02 Results of Oper and Fin Cond.

On December 27, 2024, we issued a press release announcing our results of operations for the full year of fiscal 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CTOR_OUT_21 [2025-03-25 16:32:35 -0400] 1038 Bytes | 348 tokens | Cum: 3387 tkns (42.34% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

CITIUS ONCOLOGY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

December 31, 2024 September 30, 2024 Current Assets: Cash and cash equivalents $ 112 $ 112 Inventory 14,381,369 8,268,766 Prepaid expenses 2,700,000 2,700,000 Total Current Assets 17,081,481 10,968,878 Other Assets: In-process research and development 73,400,000 73,400,000 Total Other Assets 73,400,000 73,400,000 Total Assets $ 90,481,481 $ 84,368,878 LIABILITIES AND STOCKHOLDERS EQUITY Current Liabilities: Accounts payable $ 5,874,577 $ 3,711,622 License payable 28,400,000 28,400,000 Accrued expenses 6,228,612 Due to related party 2,896,329 588,806 Total Current Liabilities 43,399,518 32,700,428 Deferred tax liability 1,992,240 1,728,000 Note payable to related party 3,800,111 3,800,111 Total Liabilities 49,191,869 38,228,539 Stockholders Eq

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CTOR_OUT_23 [2025-03-25 16:32:43 -0400] 1038 Bytes | 325 tokens | Cum: 3714 tkns (46.42% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): uity: Preferred stock - $ 0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding Common stock - $ 0.0001 par value; 100,000,000 ; 71,552,402 shares issued and outstanding at December 31, 2024 and September 30, 2024 7,155 7,155 Additional paid-in capital 87,220,249 85,411,771 Accumulated deficit ( 45,937,792 ) ( 39,278,587 ) Total Stockholders Equity 41,289,612 46,140,339 Total Liabilities and Stockholders Equity $ 90,481,481 $ 84,368,878

See notes to unaudited condensed consolidated financial statements.

CITIUS ONCOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED DECEMBER 31, 2024 AND 2023

(Unaudited)

2024 2023 Revenues $ $ Operating Expenses: Research and development 1,264,508 1,148,495 General and administrative 3,321,979 1,517,908 Stock-based compensation general and administrative 1,808,478 1,917,000 Total Op

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CTOR_OUT_25 [2025-03-25 16:33:03 -0400] 4148 Bytes | 1147 tokens | Cum: 4998 tkns (62.48% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| Volume: 451,771 | SMA50: -26.03% | Market Cap: 56.81M | Option/Short: No / No | Sales past 5Y: 0.00% | Sales Surprise: - |
+--------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| Avg Volume: 97.83K | SMA200: -80.07% | Shs Outstand: 71.55M | Short Float: 1.07% | Employees: - | EPS Surprise: -50.00% |
+--------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| Rel Volume: 4.62 | Perf Week: 39.03% | Shs Float: 3.52M | Short Ratio: 0.39 | Debt/Eq: 0.09 | P/E: - |
+--------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| RSI (14): 43.78 | Perf Month: -36.48% | Inst Own: 0.29% | Short Interest: 0.04M | Sales Y/Y TTM: - | Earnings: Feb 14 AMC |
+--------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| ATR (14): 0.12 | Perf Quarter: -25.09% | Insider Own: 95.08% | Beta: -0.08 | ROE: 3.49% | |
+--------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| SMA20: -7.13% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -46.26% | |
+--------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: Citius Oncology, Inc. Common Stock
Market Cap: N/A
Shares Outstanding: N/A
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -6659205.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.794
Average Volume: 91502.91
30-Day High: 1.25
30-Day Low: 0.5711

[Detailed Financials: Q1 2025]
- Total Assets: $90,481,481.0
- Total Liabilities: $49,191,869.0
- Total Equity: $41,289,612.0
- Current Assets: $17,081,481.0
- Current Liabilities: $43,399,518.0

[Income Statement: Q1 2025]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.09

[Cash Flow Statement: Q1 2025]
- Net Cash Flow: N/A

[Detailed Financials: FY 2024]
- Total Assets: $84,368,878.0
- Total Liabilities: $38,228,540.0
- Total Equity: $46,140,339.0
- Current Assets: $10,968,878.0
- Current Liabilities: $32,700,429.0

[Income Statement: FY 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.31

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $112
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CTOR_OUT_27 [2025-03-25 16:33:06 -0400] 676 Bytes | 167 tokens | Cum: 5428 tkns (67.85% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CTOR_IN_29 [2025-03-25 16:33:07 -0400] 126 Bytes | 29 tokens | Cum: 5521 tkns (69.01% of 8k)
==========================================================================

====================================
[2025-03-25 13:33:07] # Analysis Completed
Elapsed Time: 63.58 seconds